Market Overview

Endo's Paladin Labs Reports Canadian Introduction Of Veregen

Related ENDP
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% - Tale of the Tape
Jazz Pharmaceuticals (JAZZ) Jumps: Stock Moves 5.2% Higher - Tale of the Tape

Paladin Labs Inc., a subsidiary of Endo
International plc (Nasdaq: ENDP) (TSX: ENL) and a leading Canadian specialty
pharmaceutical company, today announced the launch of Veregen®
(sinecatechins) Ointment, 10%, a topical treatment for external genital and
perianal warts (condylomata acuminata) in immunocompetent patients aged 18
years and over.

Clinically visible warts are present in approximately 1% of sexually active
adults, making genital warts the most common sexually transmitted
infection(1). Studies have demonstrated that for individuals with external
genital warts, the reduction in their quality of life is of similar magnitude
to that seen in people with moderate to severe asthma or osteoarthritis(2).

"We are pleased to announce the launch of Veregen® in Canada," said Mark
Beaudet, President of Paladin Labs Inc. "Sexually transmitted infections
(STIs) such as external genital warts can cause tremendous psychological
stress(3). Canadians who suffer from external genital warts now have a new,
non-invasive and effective topical treatment option with a demonstrated
tolerability profile."

Paladin obtained the exclusive rights to market Veregen® in Canada from
Medigene AG in May 2014.

About Veregen: Veregen® (sinecatechins) Ointment 10% is a topical treatment
for external genital and perianal warts (condylomata acuminata) in
immunocompetent patients aged 18 years and over. It is available in a 15g
tube. The drug substance in Veregen® is sinecatechins, which is a partially
purified fraction of the water extract of green tea leaves from Camellia
sinensis (L.) O Kuntze and is a mixture of catechins and other green tea
components. The most common side effects with Veregen® Ointment are local
skin and application site reactions, but these should decrease over time(4).

Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012
European Guideline for the Management of Anogenital Warts. In addition, in
its current treatment guidelines for sexually transmitted diseases, the US
Center for Disease Control and Prevention recommends Sinecatechins 15%
Ointment (Veregen®) as a possible option for treating genital warts.

Posted-In: News Health Care FDA General

 

Related Articles (ENDP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters